Drug Development

Biotech By Anissa Gardizy — Boston Globe

With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million

Pharmalot By Ed Silverman

3 pharma trends to watch in 2021

Pharmalot By Damian Garde

Pharmalittle: Feds sue Walmart over opioid prescriptions; U.S. buys more Pfizer vaccine doses

Biotech By Adam Feuerstein

Uniqure’s hemophilia B gene therapy program on hold due to cancer diagnosis in treated patient

Pharmalot By Ed Silverman

World Trade council fails to act on proposal to waive IP rights to Covid-19 drugs and vaccines

Pharmalot By Ed Silverman

Federal watchdog urged to investigate the FDA’s handling of Biogen Alzheimer’s drug

Pharmalot By Ed Silverman

FDA finds fault with a Bristol plant, but it may not upset key approval of a cancer drug

Biotech By Adam Feuerstein

Divergent results from Agios, Forma trials for their sickle cell disease drugs

Pharmalot By Ed Silverman

A payoff for U.S. taxpayers? CDC may have claims on remdesivir patents held by Gilead

Biotech By Adam Feuerstein

Constellation’s blood cancer drug shows greater benefit, easing concerns about its future

Biotech By Adam Feuerstein

J&J’s CAR-T drug maintains strong efficacy in myeloma, shaded by neurotoxicity

Biotech By Adam Feuerstein

Genetically targeted drug from Kura Oncology induces remissions in adult leukemia patients

Biotech By Adam Feuerstein

Preliminary but ‘nothing short of great.’ New data on CRISPR treatment for blood diseases suggest cure is possible

Biotech By Damian Garde

Ovid’s treatment for a rare, untreatable disease fails in a key trial

Pharma By Ed Silverman

STAT+ Conversations: A conversation on drug pricing, policy, and access

Biotech By Adam Feuerstein

Agios drug for rare form of anemia achieves main goal of late-stage clinical trial

Biotech By Kate Sheridan

Startup Spotlight: Bullish on its asthma treatment, Kinaset forges ahead in unusual times

First Opinion By Stephen J. Ubl

What the biopharma industry is doing to build confidence in Covid-19 vaccines

Health Tech By Casey Ross

‘The trend is irreversible’: How Covid-19 could drive a shift toward decentralized trials

Health By Andrew Joseph

WHO group recommends against using remdesivir to treat hospitalized Covid-19 patients

Pharmalot By Ed Silverman

House passes a bill to close a loophole in a law that gives drug makers ‘unfair’ monopolies

Biotech By Adam Feuerstein

Concerns linger over Cytokinetics, Amgen heart failure drug despite improved study results

Pharmalot By Ed Silverman

Lawmakers introduce bill to eliminate use of dogs in pharmaceutical testing

Pharmalot By Ed Silverman

FDA requires Lilly to hire consultants to monitor quality control problems at plant making Covid-19 drug

Biotech By Adam Feuerstein

Most Read

FDA approves genetically altering pigs, to potentially make food, drugs, and transplants safer

How nanotechnology helps mRNA Covid-19 vaccines work

Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

The U.S. must support access to care and incentives for the innovation that transforms it

Trump administration outlines audacious plan to deliver ‘hundreds of millions’ of Covid-19 vaccine doses by end of 2020

The coronavirus sneaks into cells through a key receptor. Could targeting it lead to a treatment?

Ten years after the ‘Berlin patient,’ doctors announce a second person has been effectively ‘cured’ of HIV

All Coverage

With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million

3 pharma trends to watch in 2021

Pharmalittle: Feds sue Walmart over opioid prescriptions; U.S. buys more Pfizer vaccine doses

Uniqure’s hemophilia B gene therapy program on hold due to cancer diagnosis in treated patient

World Trade council fails to act on proposal to waive IP rights to Covid-19 drugs and vaccines

Federal watchdog urged to investigate the FDA’s handling of Biogen Alzheimer’s drug

FDA finds fault with a Bristol plant, but it may not upset key approval of a cancer drug

Divergent results from Agios, Forma trials for their sickle cell disease drugs

A payoff for U.S. taxpayers? CDC may have claims on remdesivir patents held by Gilead

Constellation’s blood cancer drug shows greater benefit, easing concerns about its future

J&J’s CAR-T drug maintains strong efficacy in myeloma, shaded by neurotoxicity

Genetically targeted drug from Kura Oncology induces remissions in adult leukemia patients

Preliminary but ‘nothing short of great.’ New data on CRISPR treatment for blood diseases suggest cure is possible

Ovid’s treatment for a rare, untreatable disease fails in a key trial

STAT+ Conversations: A conversation on drug pricing, policy, and access

Agios drug for rare form of anemia achieves main goal of late-stage clinical trial

Startup Spotlight: Bullish on its asthma treatment, Kinaset forges ahead in unusual times

What the biopharma industry is doing to build confidence in Covid-19 vaccines

‘The trend is irreversible’: How Covid-19 could drive a shift toward decentralized trials

WHO group recommends against using remdesivir to treat hospitalized Covid-19 patients

House passes a bill to close a loophole in a law that gives drug makers ‘unfair’ monopolies

Concerns linger over Cytokinetics, Amgen heart failure drug despite improved study results

Lawmakers introduce bill to eliminate use of dogs in pharmaceutical testing

FDA requires Lilly to hire consultants to monitor quality control problems at plant making Covid-19 drug

Asthma drug from Amgen, AstraZeneca achieves main goals in late-stage clinical trial

drug development

Most Read

All Coverage